Syqe Medical, the developer of innovative technologies in the world of medical devices, is pleased to announce the signing of an agreement with the Israeli Ministry of Defence to supply the SyqeAir Inhaler and Cartridges to all veterans prescribed medical cannabis by inhalation through the company's ground-breaking platform.
PureTech Health plc a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, had announced that it will advance LYT-300 (oral allopregnanolone) for the potential treatment of anxiety disorders and postpartum depression (PPD).
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform.
RSIP Neph (part of the RSIP Vision group) its new innovative intra-op solution that utilizes advanced Computer Vision and Artificial Intelligence algorithms, to enhance the next generation of robotic surgery.
Aculys Pharma, Inc. (“Aculys”), a company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, and Four H, Inc. (“Four H”).
BeiGene a global biotechnology company, that the U.S. Food and Drug Administration (FDA) has approved its Bruton’s tyrosine kinase inhibitor (BTKi).
Sai Life Sciences, one of India's fastest growing Contract Research, Development & Manufacturing Organizations (CRO-CDMO), the opening of a new High-Potency API (HPAPI) manufacturing facility at its cGMP API Manufacturing campus in Bidar, India.
Servier and Taiho Oncology, Inc., the release of data from SUNLIGHT, a pivotal Phase 3 global trial evaluating the combination of trifluridine/tipiracil (LONSURF®).
Canada Royal Enoch Phytomedicine Ltd., an innovative leader in ginseng and ginsenosides research and application, has the launch of a new clinical trial.
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, the availability, for in-office use, of Fortisite™ (compounded Tobramycin 1.5% + Vancomycin 5%) from its FDA‑registered and FDA‑inspected ImprimisRx® 503B outsourcing facility.